Board of Directors
Steven HoffmanCo-Founder, Chief Executive, and Chief Science OfficerSteve co-founded Tyme Inc. in 2008 as the Chief Executive Officer. With more than 30 years experience in biochemistry and physics, Steve has been the lead author on over 40 patents. For the last decade, he has focused on biopharmaceuticals for oncology, metabolic syndrome, and central nervous system disorders. Prior to working in biotech, he was involved in chemistry, aerospace and laser optics. In addition to leading the scientific development for his own companies, he has worked with multiple Fortune 500 healthcare companies, academic institutions, and the US government.
Michael DemurjianCo-Founder and Chief Operating OfficerMichael co-founded Tyme Inc. in 2008 as the Chief Operating Officer. Michael has over 25 years of executive experience with a focus on financing, operations, and marketing. He has been responsible for the overseeing the corporate and product development activities at Tyme. Prior to Tyme, Michael led the operations for Mikronite Technologies, which developed and marketed products using advanced materials science. At Mikronite, he oversaw the successful development and marketing of several products as well as implementation of collaborations with DePuy, GE and the Department of Defense.
Gerald H. Sokol MD, MSc, FCPAssociate Professor Medicine & Clinical Pharmacology
Gerald H. Sokol MD, MSc, FCP attained his medical degree from Indiana University’s Combined Degree Program in Experimental Medicine with a Masters Degree in Pharmacology and an MD. Dr. Sokol interned in Medicine at Temple University and attended the US Public Health Service Hospital in affiliation with the National Cancer Institute, Johns Hopkins, and the University of Maryland completing training in Internal Medicine. He then completed training at the Massachusetts General Hospital, Harvard Medical School in Radiation Oncology, Medical Oncology and Clinical Pharmacology attaining Board Certification in Internal Medicine, Medical Oncology, Radiation Oncology, Clinical Pharmacology, and later Quality Assurance and Utilization Review. He Is also certified in Skin Cancer Medicine from the University of Queensland. Dr. Sokol has been Chief of Radiation Oncology at the University of South Florida’s Tampa General Hospital, has built or contributed to building over 10 highly successful cancer centers. He is a board member and partner of Florida Cancer Specialists and Research Institute (the largest research group in Florida) consisting of over 190 physicians).
Dr Sokol is a decorated retired Captain in the US Navy and served as Commanding Officer of the unit at the Uniformed Services University. Dr. Sokol currently holds professorships in Medicine and Pharmacology at that institution. While maintaining a busy medical practice Dr. Sokol served on the review staff of the FDA for over 27 years as a senior regulatory scientist and officer composing over 300 white papers, IND and NDA reviews, and opinion papers. Dr. Sokol has authored or coauthored over 100 books, book chapter, abstracts, and papers on a multitude of clinical issues. He is a lifetime fellow and board member of the American Cancer Society and a fellow of the American College of Clinical Pharmacology. He has a busy teaching and research schedule and enjoys spending time with grandchildren and family.
Tommy G. Thompson currently is the Chairman and Chief Executive Officer of Thompson Holdings, and former United States Health and Human Services (HHS) Secretary and four-term Governor of Wisconsin. Governor Thompson, through his work at Thompson Holdings, continues to develop innovative solutions to the health care challenges facing American families, businesses, communities, states and the nation as a whole. These efforts focus on improving the use of information technology in hospitals, clinics and doctors’ offices; promoting healthier lifestyles; strengthening and modernizing Medicare and Medicaid; and expanding the use of medical diplomacy around the world.
From 2005 until 2009, Governor Thompson served as a senior advisor at the consulting firm Deloitte LLP and was the founding independent chairman of the Deloitte Center for Health Solutions, which researches and develops solutions to some of our nation’s most pressing health care and public health related challenges. From 2005 to early 2012, Governor Thompson served as a senior partner at the law firm of Akin, Gump, Strauss, Hauer, & Feld LLP. Governor Thompson served as Chairman of the Board of Directors of Logistics Health, Inc. from January 2011 to May 2011, and served as President from February 2005 to January 2011. He currently serves on the Board of Directors of the following public companies: Physicians Realty Trust and TherapeuticsMD, Inc., each as Chairman of the Board of Directors, Centene Corporation, C.R. Bard, Inc., Cytori Therapeutics, Inc., TherapeuticsMD, Inc. and United Therapeutics Corporation.
Timothy C. TysonBoard Member
Timothy Tyson is currently Chairman and CEO of Avara Pharmaceutical Services and Chairman at Icagen Inc. He currently serves on the board of Tyme Technologies Inc. and Marken LLC. Mr. Tyson recently served as Chairman and CEO of Aptuit LLC. He was Chairman and CEO from 2008 to 2012 leading a restructuring, acquisition and successful sale of a major portion of the company prior to stepping out as CEO to serve and guide the company as Chairman up until 2016. His corporate career spans over 30 years in the pharmaceutical industry. His expertise in leadership and management is internationally recognized. From 2002-2008, Mr. Tyson served as COO, President and CEO of Valeant Pharmaceuticals International. During this period, sales grew 69% and earnings increased 135%. He led a major restructuring of the company and established a highly effective Research and Development capability which developed a best in class epilepsy compound, Potiga, which was approved in 2010, and a promising pro-drug for hepatitis C.
Prior to joining Valeant, Mr. Tyson ran multiple divisions for GlaxoSmithKline and was a member of the Corporate Executive Team. During his 14-year tenure at GlaxoSmithKline, he was President, Global Manufacturing and Supply and ran Glaxo Dermatology and Cerenex Pharmaceuticals. Mr. Tyson was also responsible for managing all sales and marketing for GlaxoWellcome’s U.S. operations, where he launched 32 new products, eight of which reached sales of greater than $1 billion/year. Mr. Tyson held executive positions in technical operations and R & D, at Bristol-Myers from 1980-1988. Prior to his tenure at Bristol-Myers, he was a manufacturing manager at Procter & Gamble. He served on active duty as an officer in the United States Army from 1974-1979 and spent 14 years in the United States Army Reserves.
Mr. Tyson is a 1974 graduate of the United States Military Academy at West Point. While on active duty at Ft. McClellan, AL, he earned a Master of Public Administration, in 1976, and a Master of Business Administration, in 1979, from Jacksonville State University. In 2002, Mr. Tyson received a Bicentennial Leadership Award from the United States Military Academy at West Point and was named 2007 Alumnus of the Year at Jacksonville State University.
He has served on the board of directors for Valeant Pharmaceuticals International; the Pharmaceutical Research and Manufacturing Association (PhRMA); BIOCOM; on the CEO Roundtable for the University of California at Irvine; on the Dean’s Executive Forum at Cal State Fullerton; the CEO Roundtable on Cancer; the Health Sector Advisory Board at Duke University; the International Leadership Forum of the International Society of Pharmaceutical Engineers and as a visiting lecturer at Cambridge University. Mr. Tyson has served on the board of directors for non-profit organizations in Raleigh-Durham, NC and Orange County, CA and with the United Way.
Paul L. SturmanDirector
Paul is a proven, entrepreneurial, global executive with 30+ years of success in delivering exceptional results in consumer-driven businesses as measured by revenue and income growth, market share, organizational development and shareholder value. Recognized as a disciplined, decisive, and authentic leader that builds businesses through insight, clear strategic vision, prioritization of effort, and attracting and inspiring diverse teams to produce superior results. An intelligent risk-taker and change agent with a history of turning businesses around, creating and sustaining conditions for meaningful innovation, and transforming organizations organically and/or through M&A integration.
Paul Sturman was recently President and CEO of NJOY, Inc., a leading independent electronic nicotine delivery system company. NJOY’s mission was to end smoking-related death and disease by offering preferred alternatives to adult smokers and vapers around the world.
Paul joined NJOY in January ’15, after six years of successfully leading Pfizer’s $3+ billion Consumer Healthcare business, one of the largest over-the-counter (OTC) healthcare products companies in the world. He served as Global President and was responsible for all aspects of the business unit’s operations, including the development and marketing of major household brands such as Advil®, Centrum®, Emergen-C®, Caltrate®, ChapStick®, and Robitussin®. Previously, Paul had served as President, North America for J&J, where he was responsible for more than 30 brands including Listerine®, Band-Aid®, Stayfree®, Monistat®, Rogaine®, Neosporin®, and Visine®. He began his career with Warner-Lambert, stewarding brands like Trident sugarless gum and Halls Cough drops.
Over the past 25 years, Paul has dedicated his life to helping people feel better. He has held leadership positions in marketing and sales where he built brand strategies for leading consumer brands and OTC therapies. In all his roles, Paul has been a champion of consumer access to innovative self-care products.
A well-regarded executive in the industry, Paul served as Chairman of the Consumer Healthcare Products Association (CHPA) from 2009-11. CHPA is a not-for-profit association representing the makers of over-the-counter medicines and promoting the role of non-prescription medicines in America’s healthcare system through science, education, and advocacy.
Paul is also committed to giving back to the community. He is a member of the Board of Trustees of the Foundation for Morristown Medical Center. The Foundation works to advance healthcare for patients by preserving and expanding programs and services in patient care, clinical research, medical and public health education, and preventive medicine.
Paul earned his Bachelor’s degree in Biology and his Master’s degree in Business Administration from Bucknell University.
David CarberryChairman of the Audit CommitteeDavid Carberry is a retired healthcare financial executive with over 40 years of experience in the industry. Most recently, from April 2012 to June 2016 Mr. Carberry was the Chief Financial Officer of Excellis Health Solutions, LLC, a consulting and software solutions company focused on the healthcare industry. Prior to that, Mr. Carberry was Chief Financial Officer of Aldagen, a biopharmaceutical company, for three years. Mr. Carberry also served in a number of financial oversight roles within Johnson & Johnson and related divisions between 1981 and 2008, including Vice President, Finance of Independence Technology L.L.C., Johnson & Johnson/Merck Consumer Pharmaceuticals, a joint venture, and Vice President, Finance of Johnson Health Care Systems, Inc., a healthcare account management and business services provider.
James BiehlBoard MemberJim Biehl has been a partner at the law firm of Drinker Biddle & Reath LLP in Princeton, NJ since 1989 in the Corporate and Securities group. As a corporate lawyer with over 25 years of experience representing public and private companies with structuring, negotiating and managing sophisticated securities and corporate transactional matters, he has extensive experience with federal and state securities laws, public debt and equity financings, mergers and acquisitions, corporate venture transactions, joint ventures and strategic alliances, emerging company formation and management, and corporate governance matters. Jim’s industry experience includes representing big pharma, healthcare systems, healthcare consulting firms, consumer products, and medical device companies.